News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Mysthera Therapeutics Launches Initiative to Develop Innovative Therapies for Autoimmune Diseases
Tuesday, August 22, 2023Mysthera Therapeutics AG has just launched with a starting investment of million from its initial investor Forty Ventures The companys main focus is on developing novel oral treatments for complex autoimmune disorders
Willow and a Leading Innovator in Biopharmaceuticals Collaborate on Developing Eco-friendly Intermediates and Active Pharmaceutical Ingredients
Monday, August 21, 2023Willow Biosciences Inc has recently entered into a collaboration with a biopharmaceutical company listed on Nasdaq The aim of this partnership is to develop more sustainable manufacturing processes for important intermediates and active pharmaceutica...
IND Application Approval for Development Candidate GSK101 (IDE705) Targeting Pol Theta Helicase
Monday, August 21, 2023IDEAYA Biosciences Obtains IDEAYA Biosciences Inc NASDAQ IDYA a company specializing in precision medicine oncology and dedicated to the research and development of targeted therapeutics has announced the approval of an Investigational New Drug IND a...
BITT Granted FDA Acceptance of IND Application for TNFR2 Antibody
Saturday, August 19, 2023Boston Immune Technologies and Therapeutics Inc BITT a clinicalstage biotechnology firm specializing in novel treatments has received the green light from the Food and Drug Administration
Pieris Pharmaceuticals Achieves Milestone as Boston Pharmaceuticals Initiates Phase 1/2 Study of BOS-342, a Promising 4-1BB/GPC3 Immuno-oncology Bispecific
Friday, August 18, 2023Pieris Pharmaceuticals Inc recently achieved an undisclosed milestone payment from Boston Pharmaceuticals a result of successfully dosing the first patient in a phase study sponsored by Boston Pharmaceuticals
Cybin Gears Up for GMP Manufacturing of CYB003 Capsules for Phase 3 Study
Friday, August 18, 2023Cybin Inc NYSE American CYBN NEO CYBN has revealed its initiation of preparations for producing a capsule variant of CYB their exclusive deuterated psilocybin analog This advancement marks a significant stride in the companys mission to transform men...
Tetra Pharm Technologies Launches Advanced Facility for Research, Manufacturing, and Production
Thursday, August 17, 2023Tetra Pharm Technologies a biotech company based in Denmark has recently completed its purposebuilt headquarters as part of its longterm growth strategy
Sparrow Pharmaceuticals Introduces Open-label Extension in RESCUE Phase 2 Trial of SPI-62 for ACTH-dependent Cushing’s Syndrome, Enrolling First Patient
Thursday, August 17, 2023Sparrow Pharmaceuticals has made a noteworthy announcement regarding its progress in tackling Cushings syndrome a challenging medical condition
Wugen Commences Phase 1 Clinical Trial for WU-NK-101: Innovative Allogeneic Memory Natural Killer (NK) Cell Therapy Aimed at Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients
Wednesday, August 16, 2023Wugen a biotech firm in the clinical development stage has initiated the dosing of patients in the Phase clinical trial for WUNK This innovative therapy aims to treat patients suffering from relapsed or refractory acute myelogenous leukemia AML
PDS Biotech Submits Phase 3 Protocol to FDA for Initiation of VERSATILE-003 Clinical Trial
Tuesday, August 15, 2023PDS Biotechnology Corporation a company engaged in clinicalstage immunotherapy research has recently put forward updated documentation to the US Food and Drug Administration FDA
